Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioprinting – Page 12

Korean researchers have been experimenting further in the bioprinting of tracheal implants, publishing recent results in ‘Trachea with Autologous Epithelial Cells and Chondrocytes.’ The team of scientists details their use of polycaprolactone and hydrogel mixed with nasal epithelial and auricular cartilage cells.

After bioprinting an artificial trachea with these materials and tissue, they transplanted them into 15 rabbits, six of which were a control group. The goal was to find a way to overcome tracheal problems due to tumors, the most common of which are adenoid cystic carcinomas and squamous cell carcinomas. Previously there have been substantial challenges in creating viable tracheas that are anatomically correct and can produce a ciliated epithelium. Issues have arisen with infection, implants that become dislodged, have migrated, or experienced obstruction.

Read more

United Therapeutics will license, develop, and commercialize CollPlant Holdings’ recombinant human collagen (rhCollagen) and BioInk technology for 3D bioprinting of solid-organ scaffolds for human transplants, the companies said today, through a collaboration that could generate more than $44 million.

Through its wholly- owned organ manufacturing and transplantation-focused subsidiary Lung Biotechnology PBC, United Therapeutics has been granted what the companies termed an exclusive license “throughout the universe” by CollPlant to its technology for producing and using rhCollagen-based BioInk for 3D bioprinted lung transplants.

Lung Biotechnology PBC is a public benefit corporation formed to address the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply.


Medical research has taken a leap into the future as Russian scientists have managed to grow a mouse’s thyroid in zero gravity using a 3D bioprinter on the International Space Station (ISS). And human organs may be next in line.

The breakthrough device dubbed Organaut was delivered to the ISS by a Soyuz MS-11 spacecraft on December 3 by Expedition 58.

In what is no longer a plot of a sci-fi movie, the innovative device created a mouse’s thyroid in zero gravity. And the result was a success. Invitro, whose subsidiary 3D Bioprinting Solutions built the printer, told Ria Novosti: “We received photos from space. The camera clearly shows a living construction of a mouse’s thyroid being assembled.”

Read more

3D bioprinting continues to diversify as more and more companies and research organizations join the field, each bringing their own take on the technology to the table. French collaborative platform 3D.fab has an intriguing approach towards bioprinting that involves a freeform robot capable of directly printing on a part of the body. In the video below, the BioAssemblyBot prints what appears to be a bandage directly on an arm:

The “bandage” is actually a bio-ink made from the skin cells of a patient. When applied to the patient’s skin, it forms an autograft that will, within a couple of weeks, create new skin. The BioAssemblyBot is capable of both additive and contour 3D printing, as well as pick and place and assembly thanks to its interchangeable tools. It’s only one of 3D.fab’s bioprinting technologies; the platform has a few other bioprinters in development as well, including another skin printer.

Read more

After successfully transplanting the first 3D-printed cornea in an animal, North Carolina company Precise Bio has recently announced the launch of a dedicated business for creating marketable, 3D-printed products for human eyes. Founded by scientists from the Wake Forest Institute of Regenerative Medicine, this company is developing bio-fabrication printers that can restore cells, tissues, and organs. Their proprietary technology, a 4D bio-printing platform, is said to resolve existing limitations presented by other bioprinters to enable more complex tissues to be engineered for transplants and treatments. By focusing on developing marketable products for the eye, the company aims to achieve rapid advancement in its field and move to overhaul the whole organ transplant system.

When a cornea is damaged by disease or injury, a replacement is often needed to restore vision. Transplant surgery using donated corneas is an available solution, however, it relies on a deceased donor. While the waiting list in the United States is nearly non-existent, other countries require longer wait times, some over a year, before one is available. The Eye Bank Association of America estimates that around 10 million people suffer from corneal blindness that could potentially be restored via transplant surgery. An artificially manufactured cornea would overcome supply limitations while also contributing to the knowledge base to develop more complex organs such as hearts and livers.

Read more

Stem cell research firm Celprogen Inc. has been working on something quite exciting for some time now, which has remained largely under the radar until very recently. The California-based company announced it has successfully 3D printed a human brain organelle using brain stem cells. The bioprinted brain could have applications in studying neurological diseases.

More than just announcing the bioprinted brain organelle, Celprogen has also used the brain to study the “role of Microglia activation and deactivation in neurological diseases.” Through this research and experimentation, the company says it has identified and characterized 11 lead compounds that could be potential drug candidates for diseases such as Alzheimer’s, Parkinson’s and Glioblastoma.

Read more

My new article just out: The transhuman future of Quantum Archaeology & living forever is complicated, but it could still be funded by Christians if they rallied around resurrecting Jesus with 3D Bioprinting and Super Computers:

Read more

When skeletal defects are unable to heal on their own, bone tissue engineering (BTE), a developing field in orthopedics can combine materials science, tissue engineering and regenerative medicine to facilitate bone repair. Materials scientists aim to engineer an ideal biomaterial that can mimic natural bone with cost-effective manufacturing techniques to provide a framework that offers support and biodegrades as new bone forms. Since applications in BTE to restore large bone defects are yet to cross over from the laboratory bench to clinical practice, the field is active with burgeoning research efforts and pioneering technology.

Cost-effective three-dimensional (3D) printing (additive manufacturing) combines economical techniques to create scaffolds with bioinks. Bioengineers at the Pennsylvania State University recently developed a composite ink made of three materials to 3D print porous, -like constructs. The core materials, polycaprolactone (PCL) and poly (D, L-lactic-co-glycolide) acid (PLGA), are two of the most commonly used synthetic, biocompatible biomaterials in BTE. Now published in the Journal of Materials Research, the materials showed biologically favorable interactions in the laboratory, followed by positive outcomes of in an animal model in vivo.

Since bone is a complex structure, Moncal et al. developed a bioink made of biocompatible PCL, PLGA and hydroxyapatite (HAps) particles, combining the properties of bone-like mechanical strength, biodegradation and guided reparative growth (osteoconduction) for assisted natural bone repair. They then engineered a new custom-designed mechanical extrusion system, which was mounted on the Multi-Arm Bioprinter (MABP), previously developed by the same group, to manufacture the 3D constructs.

Read more